Evidence map›Paper›PMID 41250089›Full record

ArticleBMC public health2025

Vaccination uptake and associated factors among HIV pre-exposure prophylaxis (PrEP) users: insights from a retrospective cross-sectional study.

Shirley Shapiro Ben David, Daniella Rahamim-Cohen, Noam Orvieto, Bar Cohen, Limor Adler

Abstract read
In one paragraph

Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shirley Shapiro Ben DavidDivision of Health, Maccabi Healthcare Services, Ha'mered 27, Tel Aviv, 6812509, Israel. shirleys2@tauex.tau.ac.il.
Daniella Rahamim-CohenDivision of Health, Maccabi Healthcare Services, Ha'mered 27, Tel Aviv, 6812509, Israel.
Noam OrvietoDivision of Health, Maccabi Healthcare Services, Ha'mered 27, Tel Aviv, 6812509, Israel.
Bar CohenDivision of Health, Maccabi Healthcare Services, Ha'mered 27, Tel Aviv, 6812509, Israel.
Limor AdlerDivision of Health, Maccabi Healthcare Services, Ha'mered 27, Tel Aviv, 6812509, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVaccinationcoverage among individuals prescribed pre-exposure prophylaxis (PrEP) for HIV prevention is crucial for comprehensive healthcare. This study aims to evaluate vaccine uptake, characterize the vaccinated population, and identify factors influencing vaccination coverage among PrEP users in Israel.

methodsA retrospective cross-sectional study was conducted in a large outpatient setting. Patients who purchased FTC/TDF for PrEP at least once during the study period were included. Data on vaccinations, PrEP adherence, socioeconomic status, sexually transmitted infections, and prescribing physicians were extracted from electronic medical records. Vaccine coverage was assessed for hepatitis A, B, Mpox, Human Papillomavirus (HPV), and influenza. Patients were considered fully vaccinated if they had completed the recommended dose series for each vaccine or had a positive serology for hepatitis A or B. High adherence to PrEP was defined as adherence rates of over 80%. Descriptive and multivariable analyses were performed to identify factors associated with vaccine uptake. 

resultsIn 2023, a total of 2,668 patients purchased at least one PrEP prescription. All were men, with a median age of 36 years (range: 18-86). STIs occurred in 1043 (39.1%) patients, and 1222 (45.9%) had high adherence to PrEP. Fully vaccinated coverage was relatively high for hepatitis A (60.9%) and hepatitis B (58.2%), while lower rates were observed for Mpox (22.4%), HPV (27.7%), and influenza (27.6%). High adherence to PrEP was the most significant predictor of vaccination against hepatitis A, B, and Mpox (OR = 1.97, 95% CI = 1.57-2.57, p< 0.001) and for HPV (OR = 1.68, 95% CI = 1.37-2.06, p < 0.001). Family physician prescribing was also a significant predictor for vaccination against hepatitis A, B, and Mpox (OR = 1.68, 95% CI = 1.22-2.32, p = 0.001) and for HPV (OR = 1.54, 95% CI = 1.21-1.96, p < 0.001).

conclusionVaccination coverage among PrEP users is suboptimal. High PrEP adherence and prescriptions by family physicians are strong predictors of vaccination. These findings highlight the need for targeted interventions to enhance vaccine uptake within PrEP care settings, emphasizing the importance of continuity of care and a patient-centered approach.

Indexed as

HIV InfectionsPre-Exposure ProphylaxisVaccinationVaccination CoverageAdolescentAdultAgedAged, 80 and overCross-Sectional StudiesHumansIsraelMaleMiddle AgedRetrospective StudiesYoung AdultCoverageHepatitis aHepatitis bHIVHuman papillomavirusMpoxPreexposure prophylaxis (PrEP)Vaccine

Identifiers

PMID41250089
PMCPMC12625031

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.